Upstream effect for atrial fibrillation: Still a dilemma?

PACE - Pacing and Clinical Electrophysiology

Volumn 34, Issue 1, 2011, Pages 111-128

  Calã, Leonardo ^a   Martino, Annamaria ^a   Sciarra, Luigi ^a   Ciccaglioni, Antonio ^b   De Ruvo, Ermenegildo ^a   De Luca, Lucia ^a   Sette, Antonella ^a   Giunta, Giuseppe ^b   Lioy, Ernesto ^a   Fedele, Francesco ^b  

^a ASL Roma B   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

angiotensin converting enzyme inhibitors; atrial fibrillation; glucocorticoids; pharmacology; poly unsaturated fatty acids; statins; upstream therapy

Indexed keywords

AMIODARONE; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; OMEGA 3 FATTY ACID; PERINDOPRIL; PLACEBO; PRAVASTATIN; PROPAFENONE;

ACUTE HEART INFARCTION; CARDIOVASCULAR RISK; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HYPERTENSION; POST HOC ANALYSIS; POSTOPERATIVE PERIOD; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; FATTY ACIDS, OMEGA-3; GLUCOCORTICOIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 78651274819     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2010.02942.x     Document Type: Review

References (134)

1. Allessie M, Ausma J, Schotten U,. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002; 54: 230-246.
2. Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Arfanakis DA, Maliaraki NE, Lathourakis CE,. Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation. J Am Coll Cardiol 2008; 52: 211-215.
3. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A,. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-1184.
4. Goette A, Staack T, Röcken C, Arndt M, Geller JC, Huth C, Ansorge S, et al,. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000; 35: 1669-1677.
5. Ravelli F, Allessie M,. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langerdoff-perfused rabbit heart. Circulation 1997; 96: 1686-1695.
6. Li D, Shingagawa K, Pang L, Leung TK, Cardin S, Wang Z, Nattel S, et al,. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104: 2608-2614.
7. Fliser D, Buchholz K, Haller H, EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-1107.
8. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K,. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003; 41: 2197-2204.
9. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K,. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101: 2612-2617.
10. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C,. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376-380.
11. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, et al,. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926-2931. (Pubitemid 36736634)
12. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, et al,. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149: 548-557.
13. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, et al,. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152: 86-92.
14. Pizzetti F, Turazza FM, Franzosi MG, Barlera S, Ledda A, Maggioni AP, Santoro L, et al,. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: The GISSI-3 data. Heart 2001; 86: 527-532.
15. Salehian O, Healey J, Stambler B, Alnemer K, Almerri K, Grover J, Bata I, et al,. Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation study. Am Heart J 2007; 154: 448-453.
16. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, et al,. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-719.
17. L'Allier PL, Ducharme A, Keller PF, Yu H, Guertin MC, Tardif JC,. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004; 44: 159-164.
18. Heckbert SR, Wiggins KL, Glazer NL, Dublin S, Psaty BM, Smith NL, Longstreth WT Jr, et al,. Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population. Am J Hypertens 2009; 22: 538-544.
19. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanma̧ki, et al,. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616. (Pubitemid 29087980)
20. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B, Wester PO, et al,. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity: The Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-1756.
21. Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA,; VALUE Trial Group. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: The VALUE trial. J Hypertens 2008; 26: 403-411.
22. Schaer BA, Schneider C, Jick SS, Conen D, Osswald S, Meier CR,. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: A nested case-control study. Ann Intern Med 2010; 152: 78-84.
23. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ,. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol 2005; 45: 1832-1839.
24. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, et al,; ONTARGET Investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
25. Ozaydin M, Turker Y, Peker O, Erdogan D, Varol E, Dogan A, Ibrisim E,. Association between the use of non-antiarrhythmic drugs and postoperative atrial fibrillation. Int J Cardiol 2009 Mar 10. [Epub ahead of print].
26. White CM, Kluger J, Lertsburapa K, Faheem O, Coleman CI,. Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: A cohort study from the atrial fibrillation suppression trials II and III. Eur J Cardiothorac Surg 2007; 31: 817-820.
27. Miceli A, Capoun R, Fino C, Narayan P, Bryan AJ, Angelini GD, Caputo M,. Effects of angiotensin-converting enzyme inhibitor therapy on clinical outcome in patients undergoing coronary artery bypass grafting. J Am Coll Card 2009; 54: 1778-1784.
28. Hirayama Y, Atarashi H, Kobayashi Y, Horie T, Iwasaki Y, Maruyama M, Miyauchi Y, et al,. Angiotensin-converting enzyme inhibitor therapy inhibits the progression from paroxysmal atrial fibrillation to chronic atrial fibrillation. Circ J 2005; 69: 671-676.
29. Komatsu T, Ozawa M, Tachibana H, Sato Y, Orii M, Kunugida F, Nakamura M,. Combination therapy with amiodarone and enalapril in patients with paroxysmal atrial fibrillation prevents the development of structural atrial remodeling. Int Heart J 2008; 49: 435-447.
30. Komatsu T, Tachibana H, Sato Y, Ozawa M, Kunugida F, Oriii M, Nakamura M,. Long-term efficacy of upstream therapy using angiotensin-converting enzyme inhibitors and statins in combination with antiarrhythmic agents for the treatment of paroxysmal atrial fibrillation. Int Heart J 2009; 50: 465-476.
31. Fogari R, Mugellini A, Destro M, Corradi L, Zoppi A, Fogari E, Rinaldi A,. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 2006; 47: 46-50.
32. Hirayama Y, Atarashi H, Kobayashi Y, Iwasaki Y, Miyauchi Y, Ohara T, Yashima M, et al,. Long-term effects of upstream therapy on paroxysmal atrial fibrillation in patients without overt heart disease. Int Heart J 2009; 50: 141-151.
33. Yin Y, Dalal D, Liu Z, Wu J, Liu D, Lan X, Dai Y, et al,. Prospective randomized study comparing amiodarone versus amiodarone plus losartan versus amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 2006; 27: 1841-1846.
34. Palardy M, Ducharme A, Nattel S, Tardif JC, White M, Racine N, TÃtreault K, et al,. Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: Insights from the Canadian Trial of Atrial Fibrillation (CTAF). Can J Cardiol 2008; 24: 709-713.
35. Murray KT, Rottman JN, Arbogast PG, Shemanski L, Primm RK, Campbell WB, Solomon AJ, et al,. Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm 2004; 1: 669-675.
36. Zaman AG, Kearney MT, Schecter C, Worthley SG, Nolan J,. Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation. Am Heart J 2004; 147: 823-827.
37. Van Noord T, Crijns HJ, Van Den Berg MP, Van Veldhuisen DJ, Van Gelder IC,. Pretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillation. BMC Cardiovasc Disord 2005; 5: 3-8.
38. Grecu M, Olteanu RO, Olteanu SS, Georgescu CA,. Does treatment with ACE inhibitors prevent the long term recurrences of lone atrial fibrillation after cardioversion? Rom J Intern Med 2007; 45: 29-33.
39. Madrid AH, Bueno MG, Rebollo JM, Marín I, Peña G, Bernal E, Rodriguez A, et al,. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation 2002; 106: 331-336.
40. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, Chen CY, et al,. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24: 2090-2098.
41. Van Den Berg MP, Crijns HJ, Van Veldhuisen DJ, Griep N, De Kam PJ, Lie KI,. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail 1995; 1: 355-363.
42. Fogari R, Derosa G, Ferrari I, Corradi L, Zoppi A, Lazzari P, Santoro T, et al,. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J Hypertens 2008; 21: 1034-1039.
43. Madrid AH, MarÃn IM, Cervantes CE, Morell EB, Estévez JE, Moreno G, ParajÃn JR, et al,. Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004; 5: 114-120.
44. Belluzzi F, Sernesi L, Preti P, Salinaro F, Fonte ML, Perlini S,. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 2009; 53: 24-29.
45. Tveit A, Grundvold I, Olufsen M, Seljeflot I, Abdelnoor M, Arnesen H, Smith P,. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol 2007; 120: 85-91.
46. Madrid AH, Peng J, Zamora J, Marín I, Bernal E, Escobar C, Muños-Tinoco C, et al,. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: Meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol 2004; 27: 1405-1410.
47. Anand K, Mooss AN, Hee TT, Mohiuddin SM,. Meta-analysis: Inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 2006; 152: 217-222.
48. Jibrini MB, Molnar J, Arora RR,. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: A systematic review and meta-analysis. Am J Ther 2008; 15: 36-43.
49. Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, et al,; GISSI-AF investigators. Valsartan for prevention of recurrent atrial fibrillation. N Eng J Med 2009; 360: 1606-1617.
50. Richter B, Derntl M, Marx M, Lercher P, Gössinger HD,. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: No effect on ablation outcome after ablation of atrial fibrillation. Am Heart J 2007; 153: 113-119.
51. Al Chekakie MO, Akar JG, Wang F, Al Muradi H, Wu J, Santucci P, Varma N, et al,. The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation. J Cardiovasc Electrophysiol 2007; 18: 942-946.
52. Annà W, Willems R, Van Der Merwe N, Van de Werf F, Ector H, Heidbüchel H,. Atrial fibrillation after radiofrequency ablation of atrial flutter: Preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics. Heart 2004; 90: 1025-1030.
53. Schmidt BM, Schmieder RE,. Aldosterone-induced cardiac damage: Focus on blood pressure independent effects. Am J Hypertens 2003; 16: 80-86.
54. Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Kugiyama K, Harada E, et al,. Aldosterone production is activated in failing ventricle in humans. Circulation 2001; 103: 72-77.
55. Silvestre JS, Heymes C, OubÃnaAssa A, Robert V, Aupetit-Faisant B, Carayon A, Swinghedauw B, et al,. Activation of cardiac aldosterone production in rat myocardial infarction; effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99: 2694-2701.
56. Milliez P, Deangelis N, Rucker-Martin C, Leenhardt A, Vicaut E, Robidel E, Beaufils P, et al,. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 2005; 26: 2193-2199.
57. Caballero R, Moreno I, GonzÃlez T, Arias C, Valenzuela C, Delpõn E, Tamargo J,. Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels. Circulation 2003; 107: 889-895.
58. Yang SS, Han W, Zhou HY, Dong G, Wang BC, Huo H, Wei N, et al,. Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. Chin Med J (Engl) 2008; 121: 38-42.
59. Gao X, Peng L, Adhikari CM, Lin J, Zuo Z,. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J Card Fail 2007; 13: 170-177.
60. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, et al,. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized ALdactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
61. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, et al,. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
62. Pitt B,. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy. Cardiovasc Drugs Ther 1995; 9: 145-149.
63. Adam O, Neuberger HR, Böhm M, Laufs U,. Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Circulation 2008; 118: 1285-1293.
64. Tziakas DN, Chalikias GK, Stakos DA, Papanas N, Chatzikyriakou SV, Mitrousi K, Maltezos E, et al,. Effect of statins on collagen type I degradation in patients with coronary artery disease and atrial fibrillation. Am J Cardiol 2008; 101: 199-202.
65. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S,. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004; 110: 2313-2319.
66. Hanna IR, Heeke B, Bush H, Brosius L, King-Hageman D, Dudley SC Jr, Beshai JF,. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006; 3: 881-886.
67. Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi MG, Latini R, Nicolosi GL, et al., on behalf of the GISSI-HF Investigators. Effects of rosuvastatin on atrial fibrillation occurrence: Ancillary results of the GISSI-HF trial. Eur Heart J 2009; 30: 2327-2336.
68. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, Ravid S, et al,. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92: 1379-1383.
69. Ozaydin M, Turker Y, Erdogan D, Karabacak M, Dogan A, Varol E, Gonul E, et al,. The association between previous statin use and development of atrial fibrillation in patients presenting with acute coronary syndrome. Int J Cardiol 2010; 141: 147-150.
70. Ramani G, Zahid M, Good CB, Macioce A, Sonel AF,. Comparison of frequency of new-onset atrial fibrillation or flutter in patients on statins versus not on statins presenting with suspected acute coronary syndrome. Am J Cardiol 2007; 100: 404-405.
71. Adabag AS, Nelson DB, Bloomfield HE,. Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure. Am Heart J 2007; 154: 1140-1145.
72. Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, Williard A, et al., ALLHAT Collaborative Research Group. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and lipid-lowering treatment to prevent heart attack trial). J Am Coll Card 2009; 54: 2023-2031.
73. Mithani S, Akbar MS, Johnson DJ, Kuskowski M, Apple KK, Bonawitz-Conlin J, Ward HB, et al,. Dose dependent effect of statins on postoperative atrial fibrillation after cardiac surgery among patients treated with beta-blockers. J Cardiothorac Surg 2009; 4: 61-66.
74. Subramaniam K, Koch CG, Bashour A, O'Connor M, Xu M, Gillinov AM, Starr NJ,. Preoperative statin intake and morbid events after isolated coronary artery bypass grafting. J Clin Anest 2008; 20: 4-11.
75. Miceli A, Fino C, Fiorani B, Yeatman M, Narayan P, Angelini GD, Caputo M,. Effects of preoperative statin treatment on the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting. Ann Thorac Surg 2009; 87: 1853-1858.
76. Ozaydin M, Dogan A, Varol E, Kapan S, Tuzun N, Peker O, Aslan SM, et al,. Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation. Cardiology 2007; 107: 117-121.
77. MarÃn F, Pascual DA, RoldÃn V, Arribas JM, Ahumada M, Tornel PL, Oliver C, et al,. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 2006; 97: 55-60.
78. Lertsburapa K, White CM, Kluger J, Faheem O, Hammond J, Coleman CI,. Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery. J Thorac Cardiovasc Surg 2008; 135: 405-411.
79. Mariscalco G, Lorusso R, Klersy C, Ferrarese S, Tozzi M, Vanoli D, Domenico BV, et al,. Observational study on the beneficial effect of preoperative statins in reducing atrial fibrillation after coronary surgery. Ann Thorac Surg 2007; 84: 1158-1164.
80. Virani SS, Nambi V, Razavi M, Lee VV, Elayda M, Wilson JM, Ballantyne CM,. Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery. Am Heart J 2008; 155: 541-546.
81. Liakopoulos OJ, Choi YH, Kuhn EW, Wittwer T, Borys M, Madershahian N, Wassmer G, et al,. Statins for prevention of atrial fibrillation after cardiac surgery: A systematic literature review. J Thorac Cardiovasc Surg 2009; 138: 678-686.e1.
82. Liakopoulos OJ, Choi YH, Haldenwang PL, Strauch J, Wittwer T, Dörge H, Stamm C, et al,. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: A meta-analysis of over 30,000 patients. Eur Heart J 2008; 29: 1548-1559.
83. Song YB, On YK, Kim JH, Shin DH, Kim JS, Sung J, Lee SH, et al,. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Am Heart J 2008; 156: 373.e9-373.e16.
84. Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, Di Sciascio G,. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006; 114: 1455-1461.
85. Ji Q, Mei Y, Wang X, Sun Y, Feng J, Cai J, Xie S, et al,. Effect of preoperative atorvastatin therapy on atrial fibrillation following off-pump coronary artery bypass grafting. Circ J 2009; 73: 2244-2249.
86. Dernellis J, Panaretou M,. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 2005; 150: 1064.e7-1064.e12.
87. Ozadyn M, Varol E, Aslan SM, Kucuktepe Z, Dogan A, Ozturk M, Altinbas A,. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006; 97: 1490-1493.
88. GarcÃa-FernÃndez A, MarÃn F, Mainar L, RoldÃn V, MartÃnez JG,. Effect of statins on preventing recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006; 98: 1299-1300.
89. Almroth H, Höglund N, Boman K, Englund A, Jensen S, Kjellman B, Rosenqvist M,. Atorvastatin and persistent atrial fibrillation following cardioversion: A randomized placebo-controlled multicentre study. Eur Heart J 2009; 30: 827-833.
90. Xia W, Yin Z, Song Y, Qu X,. Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. Pacing Clin Electrophysiol 2009; 32: 1562-1566.
91. Tveit A, Grundtvig M, Gundersen T, Vanberg P, Semb AG, Holt E, Gullestad L,. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2004; 93: 780-782.
92. Humphries KH, Lee M, Sheldon R, Ramanathan K, Dorian P, Green M, Kerr CR,; CARAF investigators. Statin use and recurrence of atrial fibrillation after successful cardioversion. Am Heart J 2007; 154: 908-913.
93. Siu CW, Lau CP, Tse HF,. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92: 1343-1345.
94. Fauchier L, Pierre B, De Labriolle A, Grimard C, Zannad N, Babuty D,. Antiarrhythmic effect of statin therapy and atrial fibrillation. A meta-analysis of randomized controlled trials. J Am Coll Card 2008; 51: 828-835.
95. Liu T, Li L, Korantzopoulos P, Liu E, Li G,. Statin use and development of atrial fibrillation: A systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol 2008; 126: 160-170.
96. Letsburapa K, White CM, Kluger J, Faheem O, Hammond J, Coleman CI,. Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery. J Thorac Cardiovasc Surg 2008; 135: 405-411.
97. Kourliouros A, De Souza A, Roberts N, Marciniak A, Tsiouris A, Valencia O, Camm J, et al,. Dose-related effect of statins on atrial fibrillation after cardiac surgery. Ann Thorac Surg 2008; 85: 1515-1520.
98. McLean DS, Ravid S, Blazing M, Gersh B, Shui A, Cannon CP,. Effect of statin dose on incidence of atrial fibrillation: Data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials. Am Heart J 2008; 155: 298-302.
99. Goldstein RN, Ryu K, Khrestian C, Van Wagoner DR, Waldo AL,. Prednisone prevents inducible atrial flutter in the canine sterile pericarditis model. J Cardiovasc Electrophysiol 2008; 19: 74-81.
100. Shiroshita-Takeshita A, Brundel BJ, Lavoie J, Nattel S,. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc Res 2006; 69: 865-875.
101. Christiansen CF, Christiansen S, Mehnert F, Cummings SR, Chapurlat RD, Sorensen HT,. Glucocorticoi use and risk of atrial fibrillation or flutter: A population-based, case-control study. Arch Intern Med 2009; 169: 1677-1683.
102. Huerta C, Lanes SF, GarcÃa RodrÃguez LA,. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology 2005; 16: 360-366.
103. Moretti R, Torre P, Antonello RM, Zorzon M, Cazzato G,. Recurrent atrial fibrillation associated with pulse administration of high doses of methylprednysolone: A possible prophylactic treatment. Eur J Neurol 2000; 7: 130.
104. Van Der Hooft CS, Heeringa J, Brusselle GG, Hofman A, Witteman JCM, Kingma JH, Sturkenboom MC, et al,. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 2006; 166: 1016-1020.
105. Rubens FD, Nathan H, Labow R, Williams KS, Wozny D, Karsh J, Ruel M, et al,. Effects of methylprednisolone and a biocompatible copolymer circuit on blood activation during cardiopulmonary bypass. Ann Thorac Surg 2005; 79: 655-665.
106. Prasongsukarn K, Abel JG, Jamieson WR, Cheung A, Russell JA, Walley KR, Lichtenstein SV,. The effects of steroids on the occurrence of postoperative atrial fibrillation after coronary artery bypass grafting surgery: A prospective randomized trial. J Thorac Cardiovasc Surg 2005; 130: 93-98.
107. Halonen J, Halonen P, Ja̧rvinen O, Taskinen P, Auvinen T, Tarkka M, Hippela̧inen M, et al,. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: A randomized controlled trial. JAMA 2007; 297: 1562-1567.
108. Yared JP, Bakri MH, Erzurum SC, Moravec CS, Laskowski DM, Van Wagoner DR, Mascha E, et al,. Effect of dexamethasone on atrial fibrillation after cardiac surgery: Prospective, randomized, double-blind, placebo-controlled trial. J Cardiothorac Vasc Anesth 2007; 21: 68-75.
109. Halvorsen P, Raeder J, White PF, Almdahl SM, Nordstrand K, Saatvedt K, Veel T,. The effect of dexamethasone on side effects after coronary revascularization procedures. Anesth Analg 2003; 96: 1578-1583.
110. Whitlock RP, Chan S, Devereaux PJ, Sun J, Rubens FD, Thorlund K, Teoh KH,. Clinical benefit of steroid use in patients undergoing cardiopulmonary bypass: A meta-analysis of randomized trials. Eur Heart J 2008; 29: 2592-2600.
111. Baker WL, White CM, Kluger J, Denowitz A, Konecny CP, Coleman CI,. Effect of perioperative corticosteroid use on the incidence of postcardiothoracic surgery atrial fibrillation and length of stay. Heart Rhythm 2007; 4: 461-468.
112. Marik PE, Fromm R,. The efficacy and dosage effect of corticosteroids for the prevention of atrial fibrillation after cardiac surgery: A systematic review. J Crit Care 2009; 24: 458-463.
113. Dernellis J, Panaretou M,. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004; 25: 1100-1107.
114. Mozaffarian D, Geelen A, Brouwer IA, Geleijnse JM, Zock PL, Katan MB,. Effect of fish oil on heart rate in humans: A meta-analysis of randomized controlled trials. Circulation 2005; 112: 1945-1952.
115. Pepe S, McLennan PL,. Cardiac membrane fatty acid composition modulates myocardial oxygen consumption and postischemic recovery of contractile function. Circulation 2002; 105: 2303-2308.
116. Ninio DM, Murphy KJ, Howe PR, Saint DA,. Dietary fish oil protects against stretch-induced vulnerability to atrial fibrillation in a rabbit model. J Cardiovasc Electrophysiol 2005; 16: 1189-1194.
117. Sakabe M, Shiroshita-Takeshita A, Maguy A, Dumesnil C, Nigam A, Leung TK, Nattel S,. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation 2007; 116: 2101-2109.
118. Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, Van Der Meer JW, Cannon JG, et al,. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989; 320: 265-271.
119. Sarrazin JF, Comeau G, Daleau P, Kingma J, Plante I, Fournier D, Molin F,. Reduced incidence of vagally induced atrial fibrillation and expression levels of connexins by n-3 polyunsaturated fatty acids in dogs. J Am Coll Cardiol 2007; 50: 1505-1512.
120. + current in human atrial myocytes. Cardiovasc Res 2009; 81: 286-293.
121. Den Ruijter HM, Berecki G, Opthof T, Verkerk AO, Zock PL, Coronel R,. Pro- and antiarrhythmic properties of a diet rich in fish oil. Cardiovasc Res 2007; 73: 316-325.
122. Harris WS, Sands SA, Windsor SL, Ali HA, Stevens TL, Magalski A, Porter CB, et al,. Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: Correlation with erythrocytes and response to supplementation. Circulation 2004; 110: 1645-1649.
123. Macchia A, Monte S, Pellegrini F, Romero M, Ferrante D, Doval H, D'Ettorre A, et al,. Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction. Eur J Clin Pharmacol 2008; 64: 627-634.
124. Mozaffarian D, Psaty BM, Rimm EB, Lemaitre RN, Burke GL, Lyles MF, Lefkowitz W, et al,. Fish intake and risk of incident atrial fibrillation. Circulation 2004; 110: 368-373.
125. Brouwer IA, Heeringa J, Geleijnse JM, Zock PL, Witteman JC,. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam study. Am Heart J 2006; 151: 857-862.
126. Frost L, Vestergaard P,. N-3 fatty acids consumed from fish and risk of atrial fibrillation or flutter: The Danish Diet, Cancer, and Health study. Am J Clin Nutr 2005; 81: 50-54.
127. Virtanen JK, Mursu J, Voutilainen S, Tuomainen TP,. Serum long-chain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men. Circulation 2009; 120: 2315-2321.
128. McLennan PL,. Myocardial membrane fatty acids and the antiarrhythmic actions of dietary fish oil in animal models. Lipids 2001; 36 (Suppl): S111-S114.
129. Heidt MC, Vician M, Stracke SK, Stadlbauer T, Grebe MT, Boening A, Vogt PR, et al,. Beneficial effects of intravenously administered N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: A prospective randomized study. Thorac Cardiovasc Surg 2009; 57: 276-280.
130. Calà L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, De Ruvo E, Meo A, et al,. N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery. A randomized, controlled trial. J Am Coll Cardiol 2005; 45: 1723-1728.
131. Saravanan P, Bridgewater B, West AL, O'Neill SC, Calder PC, Davidson NC,. Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: A randomized, double blind, placebo controlled clinical trial. Circ Arrhythm Electrophysiol 2010; 3: 46-53.
132. Biscione F, Totteri A, De Vita A, Lo Bianco F, Altamura G,. Effetti degli acidi grassi omega-3 nella prevenzione delle aritmie atriali. Ital Heart J Suppl 2005; 6: 53-59.
133. Bianconi L, Calà L, Mennuni S, Santini L, Morosetti P, Azzolini P, Barbato G, et al,. N-3 poly-unsaturated fatty acids for the prevention of atrial fibrillation recurrence after electrical cardioversion of chronic persistent atrial fibrillation. A randomized, double-blind, mlticentre study. A7.E63 JACC 2010; 55 (Abstract).
134. Patel D, Shaheen M, Venkatraman P, Armaganijan L, Sanchez JE, Horton RP, Di Biase L, et al,. Omega-3 polyunsaturated fatty acid supplementation reduced atrial fibrillation recurrence after pulmonary vein antrum isolation. Indian Pacing Electrophysiol J 2009; 9: 292-298.